Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1210/er.2010-0013
10.1210/er.2010-0013 · External reference
10.1158/0008-5472.can-08-4531
10.1158/0008-5472.can-08-4531 · External reference
Targeting CYP17: established and novel approaches in prostate cancer
10.1016/j.coph.2008.06.004 · 2008 · External reference
Steroid 17α-hydroxylase deficiency: functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene
10.1210/jc.2009-0172 · 2009 · External reference
Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17α-hydroxylase/17, 20-lyase deficiency
10.1159/000284362 · 2010 · External reference
10.1016/j.metabol.2009.07.024
10.1016/j.metabol.2009.07.024 · External reference
Two novel mutations found in a patient with 17α-hydroxylase enzyme deficiency
10.1210/jc.2006-0469 · 2006 · External reference
Novel P450c17 mutation H373D causing combined 17α-hydroxylase /17, 20-lyase deficiency
10.1210/jc.2009-0645 · 2009 · External reference
17 α-hydroxylase/17,20-lyase deficiency as a model to study enzymatic activity regulation: role of phosphorylation
2000 · External reference
The cationic charges on Arg347, Arg358 and Arg449 of human cytochrome P450c17 (CYP17) are essential for the enzyme’s cytochrome b5-dependent acyl-carbon cleavage activities
10.1016/j.jsbmb.2004.07.005 · 2004 · External reference
Pitfalls in characterizing P450c17 mutations associated with isolated 17, 20-lyase deficiency
10.1210/jcem.86.9.7812 · 2001 · External reference
Metabolic evidence for impaired 17α-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17, 20-lyase activity
10.1530/eje-07-0712 · 2008 · External reference
Molecular evolution of adrenarche: structural and functional analysis of p450c17 from four primate species
10.1210/en.2002-220456 · 2002 · External reference
10.1016/j.jsbmb.2009.12.014
10.1016/j.jsbmb.2009.12.014 · External reference
10.1074/jbc.m114.610998
10.1074/jbc.m114.610998 · External reference
CYP17 inhibitors for prostate cancer therapy
10.1016/j.jsbmb.2010.11.005 · 2011 · External reference
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
10.1038/nature10743 · 2012 · External reference
Abiraterone and increased survival in metastatic prostate cancer
10.1056/nejmoa1014618 · 2011 · External reference
10.1093/annonc/mdt136
10.1093/annonc/mdt136 · External reference
Agents that target androgen synthesis in castration-resistant prostate cancer
10.1097/ppo.0b013e31827e0b6f · 2013 · External reference
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone
10.1016/j.ctrv.2013.03.003 · 2013 · External reference
Clinical and biochemical consequnces of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer
10.1210/jc.2011-2189 · 2012 · External reference
Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer
10.1021/jm501239f · 2015 · External reference
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
10.1021/jm040202w · 2005 · External reference
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17- (1H-benzimidazole-1-yl) androsta-5,16-diene in prostate cancer
10.1158/1535-7163.mct-08-0230 · 2008 · External reference
10.1016/j.steroids.2011.06.002
10.1016/j.steroids.2011.06.002 · External reference
10.1021/jm400048v
10.1021/jm400048v · External reference
10.1002/elps.1150181505
10.1002/elps.1150181505 · External reference
10.1002/jcc.20084
10.1002/jcc.20084 · External reference
10.1007/s10822-014-9713-7
10.1007/s10822-014-9713-7 · External reference
10.1021/ct700301q
10.1021/ct700301q · External reference
Unresolved reference
1996 · External reference
An efficient mean solvation force model for use in molecular dynamics simulations of proteins in aqueous solution
10.1006/jmbi.1996.0139 · 1996 · External reference
A limited memory algorithm for bound constrained optimization
10.1137/0916069 · 1995 · External reference
L-BFGS-B: algorithm 778: L-BFGS-B, FORTRAN routines for large scale bound constrained optimization
10.1145/279232.279236 · 1997 · External reference
Molecular -dynamics with coupling to an external bath
10.1063/1.448118 · 1984 · External reference
10.1002/(sici)1096-987x(199709)18:12<1463::aid-jcc4>3.0.co;2-h
10.1002/(sici)1096-987x(199709)18:12<1463::aid-jcc4>3.0.co;2-h · External reference
Particle mesh Ewald: an N⋅log (N) method for Ewald sums in large systems
10.1063/1.464397 · 1993 · External reference
Unresolved reference
2002 · External reference
10.1371/journal.pone.0021527
10.1371/journal.pone.0021527 · External reference
10.1021/jp1048869
10.1021/jp1048869 · External reference
Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis
2013 · External reference
